FDA allows Alnylam to restart hemophilia treatment trials

Published 6y ago

(Reuters) – The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday. All ongoing studies of the drug, fitusiran, had been pla... More »